24/7 Market News Snapshot 21 May, 2025 – Silexion Therapeutics Corp Ordinary Shares (NASDAQ:SLXN)

May 21, 2025

DENVER, Colo., 21 May, 2025 (www.247marketnews.com) – (NASDAQ:SLXN) are discussed in this article.
Silexion Therapeutics Corp has experienced a notable surge in market activity, with its shares currently priced at $1.051, representing a significant increase of 16.23% from the previous close of $0.904 during pre-market trading. This sharp rise has been accompanied by a trading volume of 2.08 million shares, indicating strong investor interest and bullish sentiment surrounding the stock. The increased trading activity suggests potential upward momentum, as SLXN appears set to breach established resistance levels. Traders are advised to keep an eye on volume trends and critical support zones to evaluate the sustainability of this uptick.

In a significant development, Silexion has successfully completed a comprehensive preclinical study of its promising RNA interference therapy candidate, SIL204. This study focused on the therapeutic efficacy of SIL204 targeting cancers associated with KRAS mutations, extending beyond pancreatic cancer to also include colorectal and lung cancers, which are prevalent in patients with these genetic changes. The preclinical evaluation included various cancer cell lines, such as GP2D and A427, which are linked to colorectal and lung cancers respectively.

Ilan Hadar, Silexion’s Chairman and CEO, emphasized the completion of this study as a critical milestone, highlighting the company’s dedication to addressing unmet medical needs in oncology. He expressed optimism about SIL204’s potential effectiveness against multiple KRAS-driven malignancies, underscoring the intent to present detailed results in the near future. Given that KRAS mutations are found in a vast majority of cases across these cancer types, the market potential for targeted therapies exceeds $30 billion annually, positioning Silexion’s innovative approach as a crucial player in the evolving landscape of cancer treatment. Stakeholders are keenly anticipating the forthcoming results, which may significantly shape the company’s future development strategies.

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.